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doi:10.1016/j.crohns.2007.07.001Abstract Infliximab has been widely used in paediatric Crohn's disease, mainly in luminal and
fistulous disease refractory to standard treatment and for extraintestinal manifestations.
Moreover, there is growing experience with its use in refractory ulcerative colitis. Infliximab has
shown similar efficacy and safety in children as in adult population. It is postulated that its early
use in paediatric inflammatory bowel disease, as a bridging treatment until the onset of action of
other immunomodulators, could reduce the use of steroids and change the natural history of the
disease as well. The effect of infliximab on mucosal healing could also contribute to the normal
growth and sexual maturation in these patients.
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The onset of inflammatory bowel disease (IBD) in paediatric
age is associated to a high rate of complications, sometimes
more severe than those occurring in adult patients. In children
and adolescents, the chronic maintenance of mucosal inflam-
mation (either with or without symptoms) has deleterious
effects upon their growth and development, and increases the
likelihood of a torpid evolution of the disease itself. In the last
years, there is a growing trend to prefer therapies able to
achieve mucosal healing – enteral nutrition,1,2 azathioprine,
infliximab3 – rather than treatments that merely ameliorate
symptoms with no improvement in mucosal damage, such as
steroids4 or mesalazine.
Protracted mucosal inflammation should result in a greater
probability of irreversible damage. Therefore, the early use of
able to heal themucosa appears to be of utmost importance. In
children with Crohn's disease, the response to infliximab
appears to be better and persist for a longer time when this
biological agent is used earlier in the course of the disease.5–7
On the other hand, adults receiving infliximab therapy asso-
ciated to azathioprine have long-term (two years) rate of
mucosal healing as high as 75%, in comparison to only 25% in
those patients receiving classical treatment with steroids.8
These data are viewed as an indirect evidence that early
“aggressive” therapymay result in amore complete remission,
thus avoiding the need for other therapies.9 Indeed, main-
tained mucosal healing with infliximab therapy has been
reported to be associated to lower complication and hospita-
lisation rates in adult Crohn's disease patients,10 thus suggest-
ing that this agent would be able to alter the natural course of
the disease.
In the present article, available data on the efficacy and
safety of infliximab inpaediatric Crohn's disease andulcerative
colitis are reviewed. In addition, the impact of this therapy on
the catch-up growth of these patients is also discussed.
2. Efficacy of infliximab in paediatric
Crohn's disease
In spite that the first reported IBD patient treated with the
anti-tumour necrosis factor (TNF) monoclonal antibody inflix-
imab – in 1993 – was a 13-year-old girl suffering from severe
Crohn's disease,11 the first trial of the use of this agent in
paediatric Crohn's disease patients was published as late as in
2000.6 In fact, most published papers on the paediatric use of
infliximab are retrospective and uncontrolled series. Most of
these studies use the paediatric Crohn's disease activity index
(PCDAI), a validated index for children and adolescents that, in
contrast to the adult Crohn's disease activity index (CDAI)
includes parameters of growth retardation as well as labora-
tory markers of inflammation, rather than subjective symp-
toms.12,13 PCDAI scores from 0 to 100 points. Scoring ≤10
points are considered as inactive disease, mild disease scoresfrom 11 to 30 points whereas scoring N30 points denote
moderate/severe disease. In most papers, clinical remission is
defined as a PCDAI≤10, and clinical response as a decrease in
PCDAI of at least 15 points (and below 30 points) from pre-
treatment value.
As in adult patients, paediatric use of infliximab has been
mostly restricted to patients with moderate/severe or fistulis-
ing disease who were refractory or dependent to steroid and
who also failed to respond to traditional immunomodulators.
However, the possibility of using this agent as a bridging therapy
to long-term immunomodulatory maintenance therapy or even
as a first line treatment to avoid the sue of steroids should be
considered, particularly in children and adolescents. In this
respect, it has been suggested that infliximab would be more
potent in children than in adults, since many paediatric
patients respond well to an early short-scheduled administra-
tion of the agent, remaining thereafter in remission for years.14
There are data suggesting that the effectiveness of
infliximab in children and adolescent depends on how early
is this agent used. Kugathasan et al.6 prospectively assessed
the short- and long-term response to a single infusion of
infliximab in 15 paediatric patients (mean age 12.8 years,
range 6–18) with refractory Crohn's disease. A rapid and
dramatic response was obtained in 14 out of 15 patients. Of
these, six patients had an “early” (b2 years) and eight had a
“late” (N2 years) disease. At 10th week, 10 of these patients
remained and remission without differences between those
with “early” or “late” disease. However, at week 32, all
patients with “late” disease had lost their response to
infliximab, as compared to those with “early” disease in
whom remission was maintained in 3/6 patients at week 52. In
a similar paper, Lionetti et al.5 report on the outcome of 22
patients with refractory and/or fistulising Crohn's disease
treatedwith infliximab “on demand”. Six and 16 patients were
classified as having “early” (b1 year), and “late” (N1 year)
disease, respectively. After 16 weeks of therapy the PCDAI was
significantly lower in those patients with “early” than in those
with “late” disease. Moreover, fistulising disease also had a
better evolution in patients with “early” disease: 5/6 in this
group had complete fistula closure, as compared to 2/7 in the
“late” disease group. These data suggest that therapeutic
response of infliximab is more sustained in patients with
shorter lived disease, so that the early use of infliximab in
paediatric Crohn's disease might be of benefit.
Very recently the REACH trial has been published.15 This is
an open, multicentric and randomized trial designed to assess
the efficacy and safety of infliximab in paediatric patients
suffering from moderate-to-severe Crohn's disease refractory
to steroids and/or immunomodulators. One-hundred and
twelve patients (mean age: 13 years, range 6–17) with Crohn's
disease diagnosed at least 3 months before, PCDAI higher than
30, and at least 8 weeks on immunomodulators, were treated
with three induction infusions (5 mg/Kg each) of infliximab at
weeks 0, 2 and 6. Those patients who responded to the
induction schedule were then randomized (1:1) at week 10 to
Figure 2 Clinical response and remission rates at week 10 in
the REACH15 and ACCENT I16 trials.
Figure 1 Clinical response and remission rates at week 54 in
the REACH trial.15
4 P. Vilar et al.receive maintenance therapy every 8 weeks (q8, n=52) or
every 12 weeks (q12, n=51) at the same dose, until week 46.
The clinical response/remission was evaluated at week 54.
Patients who lost response (PCDAI N30 or 15 or more points
increase above the week 10 value) were eligible to cross over
one time during the study to receive treatment more
frequently and/or at a higher dose, depending on the length
of time between the previous infusion and the loss of response.
If response was lost prior to 8 weeks from the previous
infliximab infusion, for both q8 and q12 groups, patients were
eligible to cross over to infliximab 10 mg/kg every 8 weeks.
Patients of the group q12 who lost response within the period
from week 8 to week 12 following the previous infusion were
eligible to cross over to infliximab 5 mg/kg every 8 weeks.
Assessment of clinical efficacy was made on an intention-to-
treat basis.
At week 10, the clinical response rate was 88.4% (91/112),
and clinical remission occurred in 58.9% of the cases (66/112).
At week 54, response and remission rates were 63.5% (33/52)
and 55.8% (29/52) in the q8 groups, and 33,3% (17/51) and
23.5% (12/51) in the q12 group (p=0.002, and pb0.001,
respectively) (Fig. 1).15 For this analysis, those patients who
crossed over or escalated dose were considered as non-
responders. About 50% of patients in the group q12 lost
response (25/51) vs. only 19% in the group q8 (10/52). Seventy-
five per cent of patientswho crossed over or escalated dose re-
gained response.15
The proportion of paediatric patients achieving clinical
response or remission at week 10 in the REACH trial was higher
that those observed in adults in the ACCENT I trial16 (Fig. 2).
Some characteristics of both trials could account for these
differences: a) All patients in the REACH trial were onimmunomodulators for at least 8 weeks, whereas only about
27% fulfilled this criterion in the ACCENT I trial, b) In the
paediatric study smoking consumption is not relevant
(although there is no evaluation of passive smoking), and c)
the mean duration of the disease was shorter in the REACH
study (1,6 vs. 7.0 years).
Taken together, the results of the REACH trial suggest that
the clinical response to infliximab, in paediatric patients with
moderate-to-severe Crohn's disease unresponsive to conven-
tional therapies, is quite similar to that in adult patients.
Infliximab is effective for both inducing and maintaining
remission or response, and for sparing steroids as well.
Maintenance infusions every 8 weeks appear superior than an
every 12-week schedule.
Although there are no conclusive data, one can speculate
with the possibility of using infliximab as first line therapy, at
the onset of the disease, in children. It is conceivable that the
early use of infliximab, with its ability for healing mucosal
damage, might be a “curative” treatment able to revert the
chronic inflammatory reaction in the bowel before it auto-
perpetuates.17
3. Efficacy of infliximab in paediatric
ulcerative colitis
The experience with infliximab in the treatment of paedia-
tric patients with ulcerative colitis is quite limited, since all
published studies are retrospective, non-controlled, and
include a small number of patients.18–26 Moreover, there is
no homogeneity either in the inclusion criteria for treatment
(although most patients had a steroid-refractory or steroid-
5Infliximab in paediatric inflammatory bowel diseasedependent moderate-to-severe disease), or the definition of
short- and long-term response. There is also a lack of con-
sensus regarding the induction and maintenance dose as well
as in the concomitant use of immunomodulators.
The recently published ACT1 and ACT2 trials show a clear
benefit of infliximab in adult patients with moderate/severe
ulcerative colitis.27 The clinical response at 8 weeks ranges
from29% to 37% in the placebo groups as compared to 64%–69%
in the therapeutic groups (pb0.001).27 At weeks 30 and 54, the
clinical response was still better with infliximab than with
placebo. A recent systematic review on the efficacy and safety
of infliximab in ulcerative colitis includes 92 children (Table 1).
The short-term (mean 2.2weeks) response and remission rates
were 75% (95%CI: 64%–83%), and 63% (95%CI: 47%–76%),
respectively. Long-term response (mean 7.9 months) reached
43% (95%CI: 33%–55%). Long-term remission was only assessed
in one series of only 14 patients24 (Table 1).
As in Crohn's disease, it would be nice to identify predictive
factors for response to infliximab. In a recent study, Ferrante
et al.29 assessed the response to infliximab in 100 adult
patients with ulcerative colitis (84 patients received a single
dose of 5mg/kg, and the remaining 37 cases were treatedwith
a three-dose induction schedule). Sixty-five per cent of
patients achieved a short-term response (either complete or
partial) as evaluated at week 4 in those treated with a single
dose, or at week 10 in those treated with three induction
doses. Responsewasworse in those patients bearing a serotype
pANCA(+)/ASCA(−), and in older patients as well.29 The age at
diagnosis, the duration of the disease, the concomitant use of
immunomodulators, and the therapeutic schedule useddid not
influence the short-term response to infliximab.29
In spite of the limitations inherent to the above-
mentioned paediatric series, one can speculate that inflix-
imab would be particularly useful in acute steroid-refractoryTable 1 Summary of the series assessing the efficacy of infliximab
from reference #28)
Author
(ref.)
n Severity (mild/
mod/severe)
Indication
(SD/SR)
Previous
IMM (n)
Inductio
doses
Eidelwein
18
12 0/6/6 8/4 8 6 (mean)
Mamula
20,21
17 1/10/6 0/17 12 1
Russell 24 14 0/5/9 0/14 7 3
Serrano 26 3 – – 3 1–6
McGinnis 22 29 0/0/29 0/29 – –
Oliva–
Hemker
23
5 – – 3 1
All studies are retrospective and non-controlled series. Dose used in ev
SD: Steroid-dependent; SR: Steroid-refractory; IMM: immunomodulatorulcerative colitis receiving concomitant immunomodulator
treatment than in patients with steroid-dependent dis-
ease18,24 (Table 1).
The optimal duration of infliximab therapy in ulcerative
colitis is not defined yet. Fanjiang et al.25 recommend to
maintain the treatment every 8 weeks for one year, and then
start with a progressive weaning, according to the clinical
response, increasing the time between doses to 10 and
12 weeks, until discontinuation. Following this policy, with a
mean follow-up of 10 months (range: 1–52) after the last
infliximab infusion, remission was maintained in all patients
who were able to discontinue the drug (80% of the initial
responders).25 At long-term, 75% of patients with either
steroid-resistant or acute disease without steroid-dependence
were able to maintain the clinical response, as compared to
only 25% of steroid-dependent patients.25 All patients received
treatment with immunomodulators both during and after
infliximab therapy. These results are in agreement with those
obtained in adult ulcerative colitis, where only 33% of steroid-
dependent patients improved, as compared to 83% in non-
steroid-dependent cases.30
In summary, on the light of published data, it is conceivable
that infliximab might be as effective in paediatric as in adult
patients with ulcerative colitis, but large randomized con-
trolled trials are needed in this particular group of patients to
confirm such a suggestion.4. Safety of infliximab in paediatric IBD
4.1. Reactions to infusion
The reported frequency of both acute and delayed reactions to
infusion of infliximab in children with IBD is similar to thatin ulcerative colitis including only paediatric patients (modified
n Repeated
infusions
Short-term
outcome
Time
(wk)
Long-term
outcome
Time
(mo)
Yes Response: 12/12
(100%)
2 Response: 8/12
(67%)
10.4
Remission: 9/12
(75%)
Remission: 9/12
(75%)
Yes Response: 14/17
(82%)
0.3 Response: 10/
16 (63%)
9.5
Remission: 6/9
(66%)
Yes Remission: 8/14
(57%)
2.6 Remission: 8/14
(57%)
12
– Response: 3/3
(100%)
– Response: 1/3
(33%)
1.5
– Response: 18/29
(62%)
4 Response: 5/29
(17%)
12
Yes Response: 5/5
(100%)
2 – –
Remission: 2/5
(40%)
ery study: 5 mg/kg.
s.
6 P. Vilar et al.reported in adult patients. A review of the paediatric literature
yields a rate of reactions to infusion of about 17%, most of them
being acute reactions (93%) defined as any event occurring
during or in the immediate 2 h following the infusion. This
frequency drops dramatically if one only takes into account
those reactions needing medical care.31 Most reactions to the
infusion occur after the second or third dose of infliximab.
Predictive factors for reactions to infusion in children include a)
female gender, b) previous history of reactions to infusion, and
c) less than four months on immunomodulator therapy.31
Most acute reactions to the infusion are easy to manage
either with antihistaminic drugs or steroids.32 Chronic (i.e.
serum sickness-like) reactions require high-dose steroid
therapy for 4–7 days, as well as prophylaxis with steroids
(48 h before 5–7 days after the infusion) in further infusions.
Prophylactic pre-medication before infusions allows to
decrease the frequency of reactions to infusion in those
patients who had developed them previously. It has been also
suggested that its use before the first infliximab infusionmight
prevent the development of these reactions. In adult patients,
the number of reactions to infusion diminish with the
concomitant use of immunomodulators, as well as with the
scheduled use of infliximab (every 8 weeks) rather than
administering it on demand. To our knowledge, there is only
one study addressing this issue in paediatric patients with an
adequate sample size (n=243).33 In this study, no benefit could
be demonstrated from either administering pre-medication
from the first infusion, using concomitant immunomodulators
or administering infliximab on a scheduled sequence, in terms
of reduction of the number of reactions to the infusion.33 It is
important to note that 7% of these reactions occurred after the
first infliximab infusion, suggesting that a placebo effect could
account for some of these events.
4.2. Infections
As in adult patients, infections associated to the use of
infliximab have been reported in paediatric patients. Non-
severe respiratory infections are the most common infectious
complications associated to infliximab use in children, but
cases of herpes zoster, tinea corporis, catheter sepsis,
meningitis due to Listeria spp., or a fatal case due to sepsis
in a malnourished and leukopenic patient undergoing multiple
surgical procedures, have been reported. To date, there are no
reports of tuberculosis or hepatitis B reactivation in paediatric
patients treated with infliximab. However, a complete
tuberculosis work-up – including anamnesis, Mantoux test
and X-ray film of the thorax – as well as serologic test for
hepatitis B virusmust be performed in any patient candidate to
be treated with infliximab.
4.3. Neoplasia
The long-term adverse consequences of the use of infliximab
still are a controversial issue. The development of neoplastic
disease is a major concern for doctors using this agent,
mainly in paediatric patients. Apparently, there is no
increased risk for developing lymphomas in patients with
IBD, but the role of conventional immunomodulators in the
development of these neoplasms is a matter of debate.
Hepatosplenic T-cell lymphoma (HSTCL) is a rare neoplasm
with about 100 cases reported in world literature. However,eight of them have been described associated to the use of
infliximab34,35 suggesting an increasing risk of this kind of
lymphoma in patients treated with this biological agent,
particularly young individuals (all reported patients were
younger than 31). Nevertheless a primary or uniquepathogenic
link between TNF blockade and the development of HSTCL in
IBD patients cannot be established, since all reported cases
were on concomitant azathioprine or 6-mercaptopurine
therapy, and there are some report of HSTCL in patients
treated only with these traditional immunomodulators.36,37
Some experts in the management of IBD – particularly
those dealing with paediatric disease – recommend not to
use immunomodulators concomitantly to infliximab for more
than six months, on the basis of recent studies which suggest
that concomitant immunomodulatory therapy adds little
benefit to the long-term maintenance therapy with inflix-
imab, in terms of prevention of relapse.38,39
4.4. Congestive heart failure
It is well known that infliximab can worsen congestive heart
failure. Recently, the preliminary results of a study assessing
the heart function (by means of electro- and echocardiogram)
during infliximab therapy, in twelve paediatric IBD patients (9
Crohn's disease, 3 ulcerative colitis), have been published.40
Seven out of 12 patients showed cardiac disturbances
consisting of dilation of the cardiac cavities (5 cases) and
septal hypertrophy (2 cases), with a direct correlation
between the length of Q–T interval and the systolic and
diastolic diameter of the left ventricle. These findings point
out to an increased risk of developing arrhythmias in these
patients. However, further and more complete studies should
be done before recommendations about cardiologic work-up
required prior infliximab therapy could be made.
4.5. Other adverse events in paediatric IBD
Recently, the case of a young Crohn's disease patient who
developed a progressive multifocal leukoencephalopathy
after infliximab therapy has been reported.41 This was a
16-year-old male who presented with a sepsis following the
second dose of infliximab. His clinical condition progressively
deteriorated, and three months later showed MRI findings
suggestive of progressive multifocal leukoencephalopathy.
Neither histological specific findings nor any infectious agent
could be documented. Neurological symptoms subsided, and
cerebral damage disappeared six moths after infliximab
discontinuation.41
5. The impact of infliximab on growth
retardation in children with IBD
5.1. IBD and growth
Delay in growth and puberal development is very frequent in
IBD – mainly in Crohn's disease – and constitutes one of the
peculiarities of this disease during this period of life. Growth
retardation may occur at the time of IBD diagnosis or later, as
a result of protracted chronic inflammation or its treat-
ment.42,43 If not treated before puberty, growth delay may
become irreversible. About 25% of Crohn's disease and 10% of
Figure 3 The GH/IGF-I axis (see text for details).
Figure 4 Changes in the mean Z-score for height in the REACH
trial.15 Mean baseline Z-score was −1.6.
7Infliximab in paediatric inflammatory bowel diseaseulcerative colitis adult patients with disease onset during
childhood have a height below the 5th percentile of the
healthy population.44
At the time of diagnosis, 88% of childrenwith Crohn's disease
have a delayed growth velocity,45 and about 33% have a height
below the 5th percentile.46 In this clinical setting, the dele-
terious role of steroid therapy on growth is of utmost relevance.
Puberty is also delayed,47 andpersists for a longer time, in those
patients with Crohn's disease with continuous activity or
frequent relapses in the pre-puberal period. In 73% of a series
of girls with Crohn's disease starting in the pre-puberal period,
menarche occurred at 16 or later.48 Induction of clinical remis-
sion in these cases is usually followed by menarche.
5.2. The growth hormone/insulin-like growth
factor-I axis
Growth hormone (GH) exerts its somatotropic actions either
directly or by means of other growth factors known as insulin-
like growth factor-I and II (IGF-I, IGF-II). IGFs are synthesized
upon GH stimulation, mainly in the liver (thus resulting in
systemic endocrine effects) but also at local level (producing
paracrine/autocrine effects). IGFs circulate bound to six
different IGF binding proteins (IGFBP-1 to 6) (Fig. 4). IGF
tissue bioavailability mostly depends on the concentrations of
the different IGFBP. In general, IGFBP-3 increases the action of
the IGFs, whereas it is inhibited by IGFBP-1 and 2.49 Increased
serum levels of IGFBP-2 are associated to growth retarda-
tion.50 GH up-regulates serum IGF-1 and IGFBP-3, and down-
regulates IGFBP-2. The integrity of the GH/IGF-I axis is of
utmost importance for a normal growth.
Both malnutrition and pro-inflammatory cytokines nega-
tively influence the GH/IGF-I axis (Fig. 3). Malnourished
children show low serum concentrations of IGF-1 which do
not normalize with the administration of exogenous GH.
Interleukin (IL)-1β, IL-6 and TNF-α decrease the IGF-I syn-
thesis by blocking the GH hepatic receptors, with indepen-
dence of the nutritional status.51 Indeed serum IGF-I levels
inversely correlate with the ESR, and the C-reactive protein
levels, whereas IGFBP-2 are directly related to ESR, IL-1β,
and IL-6.52In adults, it has been demonstrated that gastrointestinal
inflammation – no matter what is the cause – results in
decreased serum IGF-I and IGFBP-3 concentrations, as well as
increased IGFBP-1 and IGFBP-2, in the presence of normal GH
levels,53 indicating the existence of peripheral resistance to
GH. Similar results have been obtained in paediatric patients
with active IBD.54,55 These disturbances normalize upon
remission.
5.3. Infliximab and the GH/IGF-I axis
The effect of infliximab on the GH/IGF-I axis has been
recently assessed in a series of 14 adult IBD patients with low
levels of IGF-I and IGFBP-3 treated with three induction
doses (weeks 0, 2 and 6) plus two additional infusions every
eight weeks.56 Peripheral resistance to GH is apparently
reversed after the second infusion of infliximab, as judged by
the significant increase in the serum levels of IGF-I and
IGFBP-3 as compared to baseline. However, this effect is not
sustained since they return to baseline values between the
first and second maintenance dose.56 TNF blockade by
infliximab could account for the initial improvement of GH
8 P. Vilar et al.sensitivity as increased TNF activity suppresses the GH/IGF-I
axis in the liver. The late impairment of GH sensitivity during
maintenance therapy is harder to explain, but one can
speculate that during this period some degree of subclinical
mucosal inflammation might persist.
5.4. Infliximab and growth catch-up in
paediatric IBD
In the above-mentioned REACH trial,15 the Z-score for height
at weeks 0, 30 and 54was assessed in those patients withmore
than one year retardation in their bone age (as judged by the
wrist X-ray exam) (n=38). A significant improvement over the
baseline Z-score for height was observed both at weeks 30 and
56 on infliximab therapy (Fig. 4).
Borrelli et al.57 reported on a prospective series of 18
patients (mean age: 13 years, range 6–18) with moderate-to-
severe Crohn's disease refractory to conventional treatments
(azathioprine/steroids), who received 5 mg/kg infliximab at
weeks 0, 2 and 6 (followed in 8 of them by maintenance doses
every 8 weeks). At week 8 (after the three induction doses),
the PCDAI improved significantly (from 34.1±5.1 to 14.8±4.8;
pb0.01), as did the nutritional status and endoscopic/
histological parameters. Ten patients were on clinical remis-
sion (PCDAI ≤10) and 12 were in endoscopic remission. All
patients could discontinue steroids atweek 4. At 6months, the
PCDAI was significantly lower in those patients on infliximab
maintenance therapy (10.5±1.41 vs. 18.8±4.54 in those
receiving only three induction doses; pb0.05). By this time,
significant increases in both weight and height were also
observed but, again, these were much more marked in those
patients receiving infliximab on a long-term basis (Table 2).57
Improving the nutritional status and promoting catch-up
growth are major end-points of the treatment of paediatric
IBD (mainly Crohn's disease), particularly in the pre-puberal
and puberal periods. Therefore, measures of growth and
development should be routinely performed during the
follow-up of these patients, and failure to improve them
must be considered as lack of efficacy of IBD therapy.58
Catch-up is conceivably easier to achieve with treatments
able to control mucosal inflammation and restore the
nutritional status. There are reasons to believe that the
growth and development of these patients is less compro-
mised when treated with infliximab.59 Maintenance therapy
may be important in this setting.Table 2 Changes in Z-scores for weight and height in
paediatric Crohn's disease patients on infliximab therapy (from
reference #57)
Baseline At 6 moths p-value
Patients on maintenance therapy (n=8)
Z-score for weight −0.67±0.43 −0.26±0.49 b0.01
Z-score for height −1.15±0.81 −0.62±0.99 b0.01
Patient receiving only three induction doses (n=10)
Z-score for weight −0.21±0.44 −0.19±0.42 NS
Z-score for height −0.86±0.42 −0.86±0.40 NS
(NS: non-significant).References
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